Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07046923CT.gov A Study of LY4175408 in Participants With Advanced Cancer | — | Recruiting | — | — | — |
NCT06682611CT.gov Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | — | Not Yet Recruiting | — | — | — |
NCT06119581CT.gov A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT04047862CT.gov Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT03697239CT.gov High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | — | Withdrawn | — | — | — |
NCT03908333CT.gov High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | — | Withdrawn | — | — | — |
NCT03383094CT.gov Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT02124148CT.gov A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | — | Completed | — | — | — |
NCT01114958CT.gov Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases | — | Completed | — | — | — |
NCT01069081CT.gov Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT01125020CT.gov Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation | — | Unknown | — | — | — |
NCT02575859CT.gov Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Eli Lilly and Company | P3 | BB · 64 |
| Fluorouracilum | Ruijin Hospital | P4 | BBB |
| Oxaliplatin | Ruijin Hospital | P4 | BBB |
| Irinotecan | Eli Lilly and Company | P4 | BBB |
| Dexasone | Janssen Research & Development, LLC | P2 | BBB |
| Ipilimumab | 7 Hills Pharma, LLC | P3 | BB |
| Atezolizumab | UNC Lineberger Comprehensive Cancer Center | P2/3 | BB |
| Trastuzumab | City of Hope Medical Center | P3 | BB |
| Margetuximab | MacroGenics | P3 | BB |
+41 more in the Metastatic Neoplasm cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Metastatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-metastatic-neoplasm-41649
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →